Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study of chidamide and fractionated busulfan regimen in patients with AML or MDS who could not clear leukemia cells before transplantation

Next Previous
Trial Profile

A study of chidamide and fractionated busulfan regimen in patients with AML or MDS who could not clear leukemia cells before transplantation

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tucidinostat (Primary) ; Busulfan; Cytarabine; Fludarabine
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 29 Jan 2024 New trial record
  • 12 Dec 2023 Results assessing safety and preliminary efficacy of chidamide and fractionated busulfan regimen in patients with AML or MDS who could not clear leukemia cells before transplantation presented at the 65th American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top